Immunogenicity affects candidate success

Lonza’s proprietary Epibase® in silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in a biotherapeutic protein. The tool is driven by sequence information, structural bioinformatics, and experimental data. The Epibase® in silico tool uses structural characteristics of the HLA receptor along with experimentally determined binding affinities to predict potential peptide/HLA binding, a condition necessary for T cell activation.

The Epibase® in silico tool supports lead candidate selection, ranking, optimization and design for the development of biotherapeutic proteins with reduced immunogenicity risk.

Help Increase Chance of Clinical Success

  • Global population coverage, greater than 99% coverage, including 85 HLA Class II allotypes
  • Analysis includes binding affinity, promiscuity and frequency of allotypes
  • High accuracy of prediction based on in vitro correlations
  • Reduce immune response with in silico-guided engineering of epitope sequences
  • Can link in silico results with Epibase® in vitro assays for confirmation of promising candidates

Save Time and Money in Development

  • Lonza's scientific experts perform the work, analyze results and provide consultation on data interpretation
  • Rapidly assess biotherapeutic proteins with a high throughput process
  • Streamline candidate selection using in silico screening to select lower risk candidates before proceeding to in vitro screening
  • Focus R&D resources on a smaller number of protein targets with the greatest chance of success early in development